Clopidogrel
Product Images NDC 53808-1031

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 53808-1031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 75mg (Clopidogrel 75mg)

Label for Clopidogrel 75 mg tablets shows a quantity of 30 tablets. The label includes lot number P07233, expiration date 08-12-2014, and packaging by DOH Central Pharmacy in Tallahassee, FL. UPC barcode and RX only designation are present.*

FDA Label Image

Figure (Clopidogrel Fig1)

A line graph showing cumulative event rates for fatal or non-fatal vascular events over 36 months of follow-up. Two lines compare aspirin and clopidogrel, with the vertical axis representing cumulative event rate (%) and the horizontal axis representing months. The graph includes a statistical significance value (P=0.045).*

FDA Label Image

Figure (Clopidogrel Fig2)

A line graph comparing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between two groups: Placebo (+ aspirin) and Clopidogrel (+ aspirin). The graph shows lower event rates for the Clopidogrel group throughout the follow-up period, with a statistical significance indicated by P=0.00009. An additional note states that other standard therapies were used as appropriate.*

FDA Label Image

Figure (Clopidogrel Fig3)

A forest plot chart showing baseline characteristics and concomitant medication/therapy comparing the percent events for Clopidogrel (+aspirin) versus Placebo (+aspirin) across multiple subgroups. The chart includes categories such as diagnosis, age, gender, race, enzyme elevation, ST depression, diabetes, previous myocardial infarction, stroke, and various medication types. Hazard ratios with 95% confidence intervals are depicted for each subgroup to indicate the comparative efficacy of Clopidogrel versus Placebo.*

FDA Label Image

Figure (Clopidogrel Fig4)

A Kaplan-Meier survival curve showing the percentage of patients who died before first discharge over 28 days since randomization, comparing Clopidogrel to placebo. The graph indicates a 7% proportional risk reduction in deaths with Clopidogrel (7.5%) compared to placebo (8.1%).*

FDA Label Image

Figure (Clopidogrel Fig5)

A Kaplan-Meier curve showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. The graph compares Clopidogrel and Placebo groups, indicating event rates of 9.2% for Clopidogrel and 10.1% for Placebo, with a 9% proportional risk reduction (p = 0.002) for Clopidogrel.*

FDA Label Image

Figure (Clopidogrel Fig6)

A forest plot chart displaying odds ratios and 95% confidence intervals comparing events (%) between Clopidogrel and placebo across various baseline categories including sex, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, fibrinolytic agent given, prognostic index, and metoprolol allocation. The chart illustrates heterogeneity or trend tests (chi-squared and p-values) for each category and overall global heterogeneity statistics at the bottom.*

FDA Label Image

Figure (Clopidogrel Fig7)

A forest plot chart comparing the event percentages between Clopidogrel and placebo across various baseline categories including sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent given, prognostic index, and metoprolol allocation. The chart displays odds ratios with confidence intervals and includes a global heterogeneity test result.*

FDA Label Image

Change Relative To Clopidogrel Bisulfate Administered Alone (Clopidogrel Fig8)

A horizontal error bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC. Four PPIs are listed on the vertical axis: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The horizontal axis measures the mean effect and 90% confidence interval on active metabolite AUC, with values ranging approximately from 0.4 to 1.4.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel sulfate, illustrating its molecular framework including a thiophene ring, ester group, and chlorophenyl group with the sulfate moiety indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.